SPECT/CT reveals best treatment for low back pain

Molecular imaging solves the puzzle of patients' pain prior to medical intervention

2014-06-09

(Press-News.org) St. Louis, Mo. (June 9, 2014) – Low back pain is not only excruciating but also debilitating for countless sufferers. Unfortunately, not everyone responds to treatment. A molecular imaging scan in addition to a conventional bone scan can provide the necessary information about the physiological health of the spine to select the most appropriate pain-killing treatment protocol, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

Conventional imaging methods including X-ray, computed tomography and even magnetic resonance imaging show the structure of the bone, but the source of the pain is often not directly related to obvious structural changes. A hybrid molecular imaging approach called single photon emission computed tomography, combined with computed tomography (SPECT/CT), is able to go beyond structure to pinpoint the subtle physiological processes causing the pain—inflammation or infection, for example. With more clinical certainty, interventionalists can offer a range of treatments to relieve their patients' suffering. "Low back pain is an extremely common problem that affects most people at some point in their life," said Suruchi Jain, co-author of the study conducted at the Sanjay Gandhi Institute of Medical Sciences in Lucknow, India. "Inclusion of SPECT/CT with conventional bone scan could help reduce unnecessary treatments and provide vital information for the proper management of patients in pain." The aim of the study was to compare the difference in pain relief following clinical pain management between two groups of patients. A total of 80 adults between the ages of 20 and 80 years of age were included in the randomized, double-blind trial. One group underwent conventional bone scans with the addition of SPECT/CT, and a second group acted as a control, with no imaging provided prior to intervention. Patients were evaluated on a scale according to percentage of pain relief compared to their baseline level prior to treatment. Patients with 50 percent or greater pain relief were much more likely to be in the bone scan group. A total of 28 patients in the bone scan group achieved between 70 and 100 percent pain relief, compared to only 10 subjects in that range in the control group. Clinical diagnosis was altered for 23 out of 40 patients in the bone scan group, and three new conditions were unveiled as a result of the bone scan. This evidence could improve access to SPECT/CT for these patients. "The findings of this study suggest that incorporation of a bone scan with SPECT/CT in work-ups of low backache patients could lead to more widespread use of this nuclear medicine procedure in the future by increasing the confidence level of pain-treating physicians prior to interventions, thus improving their outcome," Jain said. INFORMATION: Scientific Paper 91: Suruchi Jain, Sanjay Gambhir, Prasanta Pradhan, Murthy Siddegowda, Nuclear Medicine, Sanjay Gandhi Institute of Medical Sciences, Lucknow, India; Anuj jain, Anil Agrawal, Anaesthesiology, Sanjay Gandhi Institute of Medical Sciences, Lucknow, India,"Effect of inclusion of bone scan with SPECT/CT in the workup of low back pain patients prior to interventional procedure," SNMMI's 61th Annual Meeting, June 7󈝷, 2014, St. Louis, Missouri.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

ELSE PRESS RELEASES FROM THIS DATE:

Chemo-radionuclide therapy halts neuroendocrine cancer

2014-06-09

St. Louis, Mo. (June 9, 2014) – Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. The research findings show that the experimental therapy led to stabilization or regression of patients' cancer in about 70 percent of cases a year after completion of the treatment, now called peptide receptor chemo-radionuclide therapy (PRCRT). The therapy is ...

Opti-SPECT/PET/CT: 5 different imaging systems now combined

2014-06-09

St. Louis, Mo. (June 9, 2014) – Taking their pick, biomedical researchers can now conduct five different imaging studies in one scan with a state-of-the-art preclinical molecular imaging system that scientists unveiled during the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. The imaging device allows single photon emission tomography (SPECT), positron emission tomography (PET), X-ray computed tomography, fluorescence and bioluminescence imaging—powerful imaging techniques that provide different information about anatomy and physiological processes ...

Radioluminescence tells the story of single cells

2014-06-09

St. Louis, Mo. (June 9, 2014) – With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. A resolution of 20 micrometers or microns—about a quarter of the diameter of a single human hair—is made possible with an imaging technique that ...

Enzyme-inhibition could revolutionize molecular imaging

2014-06-09

St. Louis, Mo. (June 9, 2014) – The prominent role a single enzyme plays in cancer imaging has eluded researchers for years, but not anymore. This discovery could pave new avenues in nuclear medicine. The enzyme, called neutral endopeptidase (NEP), has a way of breaking down most radiopeptide imaging agents in the body. Researchers have developed an elegant new concept that improves molecular imaging, according to study results presented during the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. The sneaky enzyme has evaded studies with peptide ...

Molecular imaging gets to the root of rheumatoid arthritis

2014-06-09

St. Louis, Mo. (June 9, 2014) – Rheumatoid arthritis causes chronic pain for almost half of adults by the time they retire, but a new molecular imaging technique can visualize inflammation in the joints, giving doctors a clear read on chronic pain and possible joint destruction, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. In order to image arthritis inside the joints, researchers used multiple molecular imaging systems, positron emission tomography (PET) and single photon emission tomography (SPECT), both of which image ...

Depression in the elderly linked to Alzheimer's risk

2014-06-09

St. Louis, Mo. (June 9, 2014) – Many people develop depression in the latest stages of life, but until now doctors had no idea that it could point to a build up of a naturally occurring protein in the brain called beta-amyloid, a hallmark of Alzheimer's disease. In fact, late-life depression could become a major risk factor for developing Alzheimer's faster than others, according to research unveiled at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. Alzheimer's disease is a currently incurable neurodegenerative disease with marked protein ...

REM sleep disturbance signals future neurodegenerative disease

2014-06-09

St. Louis, Mo. (June 9, 2014) – How many millions of people suffer from sleep disturbance? One sleep disorder in particular, called REM behavior disorder, could be a sign of impending neurodegenerative disease, including Parkinson's and dementia, say scientists presenting their research at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. Researchers are not sure why spontaneous and unexplained disturbance in REM sleep should lead to a neurodegenerative disease like Parkinson's, but new longitudinal imaging data show a clear correlation between ...

A few circulating cancer cells could cue risk of metastases

2014-06-09

St. Louis, Mo. (June 9, 2014) – A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients' chances of survival, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. Metastasis accounts for an estimated 90 percent of cancer deaths. For decades, researchers tried to develop a way to gauge a cancer's risk of metastasizing from a blood sample—the long-sought-after liquid biopsy. Today there are numerous methods available to isolate lone cells. ...

Molecular imaging finds novel way to knock down breast cancer

2014-06-09

St. Louis, Mo. (June 9, 2014) – For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells—specifically those testing positive for human epidermal growth factor receptor 2 (HER2). A recent innovation in breast cancer biomarkers seeks the HER3 receptor instead, which could mean more comprehensive breast cancer imaging and potential treatments, say experts presenting data during the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. Breast cancer is one of the most prevalent forms of ...

PSMA-based imaging traces even treatment-resistant prostate cancer

2014-06-09

St. Louis, Mo. (June 9, 2014) – Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized—but some cases simply do not respond to this treatment. A groundbreaking molecular imaging agent has been developed to help clinicians find as much cancer as possible, whether it is responding favorably or not, in an effort to improve clinical decision making for these patients, say researchers at the Society of Nuclear ...

SPECT/CT reveals best treatment for low back pain

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: